CA
NZ
UK
AU
IND
US
Net revenues increased 7% including the currency headwind, mainly related to the U.S. dollar and Japanese yen. The increase in cars and spare parts was driven by product mix and higher personalizations, which surpassed 21% of total revenues from cars and spare parts and …
The quarter included two first-ever FDA approvals for gene therapies. Genglycos, an AAV8 therapy for glycogen storage disease type Ia, receivedAccelerated Approvalin August for patients aged eight and older, and Fayuvi, an AAV9 therapy for Sanfilippo syndrome type A, received standard full approval in …
The net loss was USD 17.7 million againstNet Incomeof USD 76.9 million. The company attributes the swing primarily to USD 79.1 million of share-based compensation expense for stock awards granted to full-time and part-time employees to commemorate its 50th anniversary, plus USD 6.9 million …
For the nine months ended September 30, 2026, net sales were USD 1,046,244 thousand versus USD 901,311 thousand, and gross profit was USD 569,075 thousand versus USD 482,864 thousand.
GAAP book value per common share declined 4.9% to USD 6.56 from USD 6.90, and the economic return on book value was negative 2.3%. ADividendof USD 0.18 per share was paid, the same as in the second quarter. Chief Executive Officer Christopher Abate said …
Product sales were USD 24,546 thousand versus USD 30,340 thousand, and license and collaboration revenue was USD 40 thousand with none in the prior-year quarter. For the nine months ended September 30, 2026, total revenue was USD 89,220 thousand versus USD 101,871 thousand, including …
Consolidated adjusted EBITDA was USD 52 million, including USD 2 million of tariff-related costs. Year-to-dateCash FlowfromOperating Activitieswas USD 66 million and adjusted free cash flow was USD 2 million.
For the nine months, revenue was USD 344.2 million versus USD 287.7 million, net income was USD 87.8 million versus USD 86.6 million, and earnings per share were USD 1.23 versus USD 1.21. The diluted share count was 71.0 million versus 71.8 million. Chairman …
The net loss was USD 65.5 million againstNet Incomeof USD 0.5 million. The company attributes it primarily to a non-cash goodwill impairment charge of USD 57.3 million and restructuring costs of USD 5.5 million. Management ran an interim goodwill review after a fall in …
Adjusted EBITDA was USD 121 million, compared with USD 144 million in the prior quarter. Adjusted EBITDAMarginexcluding reimbursables was 29.7%, versus 33.5% in the second quarter. President and Chief Executive Officer Samir Ali said the company is delivering on its commitment to convert backlog …
Please wait processing your request...